While most current research focuses on prolonging the half-life of GLP-1 through chemical modification, this study approached obesity management from three perspectives: improving drug dispersion and bioavailability using high-speed jet injection, extending half-life with sustained-release formulations, and maintaining drug-induced weight loss through dietary control. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.